Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Zalicus to discontinue Z-160 development following phase II results

Nov. 12, 2013

Sanofi presents preclinical results for SAR-502250

Nov. 12, 2013

FDA approves Aptiom as adjunctive treatment for partial-onset seizures

Nov. 11, 2013

FDA clears CERC-301 for phase II study in major depression

Nov. 11, 2013

CereSpir acquires rights to cognitive impairment treatment candidate

Nov. 11, 2013

Evotec and Johnson & Johnson Innovation establish collaboration in Alzheimer's disease

Nov. 8, 2013

Researchers in the U.S. patent novel neuroprotective oligopeptides

Nov. 8, 2013

New model of familial dysautonomia allows testing of therapeutic strategies

Nov. 8, 2013

Trophos completes pivotal phase II/III study of olesoxime in spinal muscular atrophy in Europe

Nov. 7, 2013

Tricyclo-DNA oligonucleotides show promise for SMA and DMD

Nov. 7, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...